scholarly journals Efficacy and safety of Shengmai injection as an adjunctive therapy on sepsis

Medicine ◽  
2022 ◽  
Vol 101 (2) ◽  
pp. e28493
Author(s):  
Yue Han ◽  
Guofu Zhong ◽  
Xiao Chang ◽  
Mujuan Xu ◽  
Mingtai Chen ◽  
...  
Keyword(s):  
Adjunctive Therapy ◽  
Efficacy And Safety ◽  
Shengmai Injection

Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide

2006 ◽  
Vol 8 (3) ◽  
pp. 522-526 ◽  
Author(s):  
William A. Tosches ◽  
Jonathan Tisdell
Keyword(s):  
Adjunctive Therapy ◽  
Efficacy And Safety ◽  
Term Efficacy

P.2.f.027 The efficacy and safety of basimglurant as adjunctive therapy in major depression; a randomised, double-blind, placebo-controlled study

2014 ◽  
Vol 24 ◽  
pp. S468 ◽  
Author(s):  
J.A. Quiroz ◽  
P. Tamburri ◽  
D. Deptula ◽  
L. Banken ◽  
U. Beyer ◽  
...  
Keyword(s):  
Major Depression ◽  
Adjunctive Therapy ◽  
Controlled Study ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Double Blind Placebo

Efficacy and safety of lacosamide as an adjunctive therapy for refractory focal epilepsy in paediatric patients: a retrospective single-centre study

2015 ◽  
Vol 17 (4) ◽  
pp. 436-443 ◽  
Author(s):  
Jean-François Toupin ◽  
Anne Lortie ◽  
Philippe Major ◽  
Paola Diadori ◽  
Michel Vanasse ◽  
...  
Keyword(s):  
Adjunctive Therapy ◽  
Focal Epilepsy ◽  
Efficacy And Safety ◽  
Single Centre ◽  
Centre Study ◽  
Paediatric Patients ◽  
Single Centre Study

The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder

2007 ◽  
Vol 68 (06) ◽  
pp. 843-853 ◽  
Author(s):  
Robert M. Berman ◽  
Ronald N. Marcus ◽  
René Swanink ◽  
Robert D. McQuade ◽  
William H. Carson ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Adjunctive Therapy ◽  
Efficacy And Safety ◽  
Major Depressive

scholarly journals Effect of acupuncture for methadone maintenance treatment patients: study protocol of a randomized clinical trial

Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Hao Wen ◽  
Shichao Xu ◽  
Jingchun Zeng ◽  
Shuqi Ge ◽  
Yuan Liao ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Adjunctive Therapy ◽  
Opioid Dependence ◽  
Methadone Maintenance ◽  
Controlled Trial ◽  
Urine Test ◽  
Efficacy And Safety ◽  
Opioid Use ◽  
Randomized Controlled ◽  
Sf 36

Abstract Background Opioid dependence is an increasing public health problem all over the world. Patients with opioid dependence have to receive methadone maintenance therapy (MMT) as replacement therapy for years or even for their entire life. Acupuncture as a kind of therapy has been used to treat substance dependence for many years. Jin’s three-needle acupuncture (JTN), a type of acupuncture technique, has been applied to treat various diseases for several decades. However, JTN as an acupuncture technique has not been used to treat patients receiving MMT. Therefore, we designed a randomized controlled trial to evaluate the efficacy and safety of acupuncture as adjunctive therapy for patients receiving MMT. Methods/design This study is a parallel-arm, randomized controlled trial that aims to evaluate the efficacy and safety of acupuncture as adjunctive therapy for patients receiving MMT. A total of 140 eligible participants who range in age from 18 to 60 years and fulfil the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V), for opiate dependence will be enrolled into this study. All eligible participants will be randomly assigned to the acupuncture group or routine group in a 1:1 allocation ratio. Participants who are enrolled in the acupuncture group will receive MMT and JTN treatment for 30 min per session. Meanwhile, those who are assigned to the routine arm will receive MMT only. All 18 sessions of JTN treatment will be delivered over 6 weeks (3 per week) and followed by a 4-week follow-up period. The primary outcome measure will be the visual analogue scale (VAS) for drug craving and the daily consumption of methadone (DCOM). Secondary outcome measures will include the urine test for opioid use, the 36-item Short Form Survey (SF-36), the Beck Anxiety Inventory (BAI), the Beck Depression Inventory II (BDI-II) and Pittsburgh sleep quality index (PSQI). VAS, DCOM, BAI, BDI-II and the urine test for opioid use will be evaluated at baseline, the second week, the fourth week, the sixth week and the tenth week. SF-36 and PSQI will be assessed at baseline, the fourth week, the sixth week and the tenth week. Discussion The results of this trial will provide evidence on the efficacy and safety of acupuncture as adjunctive therapy for patients receiving MMT. Trial registration Chinese Clinical Trial Registry ChiCTR1900026357. Registered on 2 October 2019.

scholarly journals Meta-Analysis on the Efficacy and Safety of Hyperbaric Oxygen as Adjunctive Therapy for Vascular Dementia

2019 ◽  
Vol 11 ◽  
Author(s):  
Qiang You ◽  
Lan Li ◽  
Su-qin Xiong ◽  
Yu-fen Yan ◽  
Dan Li ◽  
...  
Keyword(s):  
Vascular Dementia ◽  
Hyperbaric Oxygen ◽  
Adjunctive Therapy ◽  
Meta Analysis ◽  
Efficacy And Safety

scholarly journals Efficacy and Safety of Shengmai Injection for Chronic Heart Failure: A Systematic Review of Randomized Controlled Trials

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Yanping Wang ◽  
Xu Zhou ◽  
Xiaofan Chen ◽  
Fei Wang ◽  
Weifeng Zhu ◽  
...  
Keyword(s):  
Heart Failure ◽  
High Risk ◽  
Chronic Heart Failure ◽  
Western Medicine ◽  
Meta Analysis ◽  
Risk Of Bias ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Shengmai Injection ◽  
Randomized Controlled

Background. Shengmai injection (SMI) is made from purified ginseng, Radix Ophiopogonis, and Schisandra chinensis. It has cardiotonic effects and is clinically used for the adjuvant treatment of chronic heart failure (CHF). However, its efficacy and safety are uncertain. The purpose of this study was to systematically evaluate the existing efficacy and safety evidence in randomized controlled trials (RCTs) that studied SMI for the treatment of CHF. Methods. PubMed, Embase, Cochrane Library, clinicaltrials.gov, CNKI, Wanfang, VIP, and CBM databases were searched up to September 10, 2019. RCTs that compared basic Western medicine treatment with SMI + basic Western medicine were included. The Cochrane Collaboration Risk of Bias Tool was used to assess the risk of bias in the RCTs. The meta-analysis used the random effects model; the mean difference (MD) and 95% confidence intervals (CIs) were combined using the inverse variance method, and the Mantel–Haenszel method was used to combine the relative risk (RR) and 95% CIs. Heterogeneity was assessed using I2 and Q tests, and the source of heterogeneity was explored by analyzing three preset subgroup hypotheses. Results. A total of 20 RCTs were included (n = 1562), with a moderate-to-high risk of bias. The meta-analysis showed that, compared with Western medicine alone, SMI adjuvant therapy significantly improved cardiac function indicators, including left ventricular ejection fraction (MD 6.8%, 95% CI 4.68 to 8.91), stroke volume (MD 9.81 ml, 95% CI 5.67 to 13.96), cardiac output (MD 0.96 L/min, 95% CI 0.66 to 1.25), and cardiac index (MD 0.53 L/min, 95% CI 0.36 to 0.70); heterogeneity was generally high among these outcomes. Compared with the controls, patients receiving SMI adjuvant therapy also had a higher response to treatment (RR 2.89, 95% CI 2.10 to 3.99; I2 = 0%), a greater decrease in brain natriuretic peptide levels (MD −284.66 ng/l, 95% CI −353.73 to −215.59, I2 = 0%), and a greater increase in six‐minute walk test performance (MD 70.67 m, 95% CI 22.92 to 118.42; I2 = 84%). Nine studies reported mild adverse events, such as gastrointestinal reactions, and no serious adverse events were reported. Conclusion. Currently, available evidence indicates that SMI, as an adjuvant for basic Western medicine treatment, can improve the cardiac function of patients with CHF with good safety outcomes. Because of the high risk of bias among the included RCTs and the large heterogeneity of partial outcomes, the findings of this study must be verified by high-quality studies with large sample sizes.

Sign in / Sign up

Export Citation Format

Share Document